Puramed amends $350,000 TCA Global Credit Master Fund convertible note

Company also revises committed equity facility agreement with investor

By Devika Patel

Knoxville, Tenn., July 16 - Puramed Bioscience Inc. amended a $350,000 convertible promissory note held by TCA Global Credit Master Fund, LP on July 9, according to an 8-K filed Tuesday with the Securities and Exchange Commission. The note was sold on June 29, 2012.

The amended 12% note has a principal of $368,757 and matures on Jan. 1, 2014. It is convertible into common shares at a price equal to 85% of the average daily volume weighted average price of the stock during the five trading days preceding conversion. The note may be prepaid.

The company also amended a June 29, 2012 committed equity facility agreement with the investor to revise certain definitions.

TCA also will receive a $75,000 fee in common stock.

Based in Schofield, Wis., Puramed BioScience develops and markets a line of non-prescription medicinal or healthcare products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.